Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Agios’ next-gen PK drug fails blood cancer study but sickle cell disease ambitions remain undimmed

Agios’ next-gen PK drug fails blood cancer study but sickle cell disease ambitions remain undimmed

  • May 29, 2026

Agios Pharmaceuticals’ next-gen pyruvate kinase (PK) activator has failed a phase 2 study in a group of rare blood cancers, although the biopharma is still holding out hope in sickle cell disease (SCD).

Leave A Comment

Fields (*) Mark are Required